Clinical Trial Update: The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating duloxetine for cognition improvement in mild cognitive impairment with comorbid depression has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Major Depressive Disorder

Drugs mentioned

• Duloxetine (DULOXETINE)

Snippet

Sponsor: University of North Texas Health Science Center | Conditions: Mild Cognitive Impairment, Depression | Phase 4 | Status: COMPLETED